-
公开(公告)号:ZA201605990B
公开(公告)日:2019-12-18
申请号:ZA201605990
申请日:2016-08-29
Applicant: VERTEX PHARMA
Inventor: AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN-MIGUEL , KAY DAVID (DECEASED) , KNEGTEL RONALD , MIDDLETON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I:or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A:or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
-
公开(公告)号:SI2941432T1
公开(公告)日:2018-07-31
申请号:SI201331041
申请日:2013-12-06
Applicant: VERTEX PHARMA
Inventor: AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN-MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDLETON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: A61K31/00 , C07D487/00 , A61P35/00
-
公开(公告)号:SG11201504467YA
公开(公告)日:2015-07-30
申请号:SG11201504467Y
申请日:2013-12-06
Applicant: VERTEX PHARMA
Inventor: AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN-MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDLETON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: A61K31/495 , C07D487/04 , A61P35/00
Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I:or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A:or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
-
公开(公告)号:HUE055618T2
公开(公告)日:2021-12-28
申请号:HUE18212042
申请日:2013-12-06
Applicant: VERTEX PHARMA
Inventor: AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN-MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDELTON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: C07D487/04 , A61P35/00 , C07D453/02 , C07D471/08 , C07D498/04 , C07D498/10
-
35.
公开(公告)号:SI3486245T1
公开(公告)日:2021-09-30
申请号:SI201331909
申请日:2013-12-06
Applicant: VERTEX PHARMA
Inventor: AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN-MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDELTON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: C07D487/00 , A61K31/00 , A61P35/00 , C07D453/00 , C07D471/00 , C07D491/00 , C07D498/00
-
36.
公开(公告)号:DK3486245T3
公开(公告)日:2021-07-19
申请号:DK18212042
申请日:2013-12-06
Applicant: VERTEX PHARMA
Inventor: DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN-MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDELTON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER , AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA
IPC: C07D487/04 , A61K31/495 , A61P35/00 , C07D453/02 , C07D471/08 , C07D491/107 , C07D498/04 , C07D498/10
-
37.
公开(公告)号:LT3418281T
公开(公告)日:2021-01-11
申请号:LT18159811
申请日:2013-12-06
Applicant: VERTEX PHARMA
Inventor: AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMINE , JIMENEZ JUAN-MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDLETON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: C07D487/04 , A61K31/495 , A61P35/00 , C07D453/02 , C07D471/08 , C07D487/08 , C07D491/107 , C07D498/04 , C07D498/10
-
公开(公告)号:ES2768678T3
公开(公告)日:2020-06-23
申请号:ES14815187
申请日:2014-12-05
Applicant: VERTEX PHARMA
Inventor: CHARRIER JEAN-DAMIEN , DAVIS CHRISTOPHER , FRAYSSE DAMIEN , ETXEBARRIA I JARDI GORKA , PEGG SIMON , PIERARD FRANCOISE , PINDER JOANNE , STUDLEY JOHN , ZWICKER CARL , SANGHVI TAPAN , WALDO MICHAEL , MEDEK ALES , SHAW DAVID , PANESAR MANINDER , ZHANG YUEGANG , ALEM NAZIHA
IPC: C07D487/04 , A61K31/519 , A61P35/00 , C07B59/00
Abstract: Un compuesto de Fórmula I-B:**Fórmula** o una sal farmacéuticamente aceptable del mismo, en la que: Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 es independientemente hidrógeno o deuterio; con la condición de que al menos uno de Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 es deuterio; cada uno de X1, X2, X4, X5, X6, X7, X8 y X9 es independientemente 12C o 13C; X3 es independientemente -12C(O)- o -13C(O)-; y en la que a) Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 son deuterio, e Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10 e Y11 son independientemente hidrógeno o deuterio; b) Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 son deuterio, e Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10,e Y11 son hidrógeno; opcionalmente donde: i) X1, X2, X4, X5, X6, X7, X8 y X9 son 12C; y X3 es -12C(O)-; o en donde: ii) X1, X4, X5, X6, X7, X8 y X9 son 12C; X3 es -13C(O)-; y X2 es 13C; c) Y11, Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 son deuterio, e Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9 e Y10 son independientemente hidrógeno o deuterio; opcionalmente donde Y11, Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 son deuterio, e Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9 e Y10 son hidrógeno. d) donde Y2, Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 son deuterio, e Y1, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10 e Y11 son independientemente hidrógeno o deuterio; opcionalmente donde Y2, Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 son deuterio, e Y1, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10,e Y11 son hidrógeno; e) Y12, Y13, Y18 e Y19 son deuterio, e Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y14, Y15, Y16 e Y17 son hidrógeno o deuterio; opcionalmente donde Y12, Y13, Y18 e Y19 son deuterio, e Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y14, Y15, Y16 e Y17 son hidrógeno. f) en donde Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10 e Y11 son deuterio, e Y1, Y2, Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 son independientemente deuterio o hidrógeno; opcionalmente donde Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10 e Y11 son deuterio, e Y1, Y2, Y12, Y13, Y14, Y15, Y16, Y17, Y18,e Y19 son hidrógeno; g) Y2 e Y11 son deuterio, e Y1, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 son deuterio o hidrógeno; opcionalmente en donde Y2 e Y11 son deuterio, e Y1, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 son hidrógeno. h) Y2 es deuterio, e Y1, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 son deuterio o hidrógeno; opcionalmente en donde Y2 es deuterio, e Y1, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y12, Y13, Y14, Y15, Y16, Y17, Y18,e Y19 son hidrógeno; opcionalmente donde: i) X1, X2, X4, X5, X6, X7 y X8 son 12C; X3 es -12C(O)-; y X9 es 13C; o ii) X1, X2, X8 y X9 son 12C; X3 es -12C(O)-; y X4, X5, X6 y X7 son 13C; iii) X2, X4, X5, X6, X7, X8 y X9 son 12C; X3 es -12C(O)-; y X1 es 13C; o iv) X2, X4, X5, X6, X7 y X9 son 12C; X3 es -13C(O)-; y X1 y X8 son 13C; o j) Y11 es deuterio, e Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y12, Y13, Y14, Y15, Y16, Y17, Y18 e Y19 son independientemente hidrógeno o deuterio; opcionalmente en donde Y11 es deuterio, e Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y12, Y13, Y14, Y15, Y16, Y17, Y18,e Y19 son hidrógeno; opcionalmente donde: X1, X4, X5, X6, X7, X8 y X9 son 12C; X3 es -12C(O)-; y X2 es 13C.
-
公开(公告)号:CY1120232T1
公开(公告)日:2019-07-10
申请号:CY181100515
申请日:2018-05-18
Applicant: VERTEX PHARMA
Inventor: AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDLETON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: C07D487/04 , A61K31/495 , A61P35/00
Abstract: Ηπαρούσαεφεύρεσηαναφέρεταισεενώσειςχρήσιμεςωςαναστολείςκινάσηςπρωτεΐνης ATR. Ηεφεύρεσηαναφέρεται, επίσης, σεφαρμακευτικώςαποδεκτέςσυνθέσεις, οιοποίεςπεριέχουντιςενώσειςαυτήςτηςεφεύρεσης, μεθόδουςθεραπευτικήςαγωγήςδιαφόρωνασθενειών, διαταραχώνκαικαταστάσεωνμεχρήσητωνενώσεωναυτήςτηςεφεύρεσης, διαδικασίεςγιατηνπαρασκευήτωνενώσεωναυτήςτηςεφεύρεσης, ενδιάμεσαγιατηνπαρασκευήτωνενώσεωναυτήςτηςεφεύρεσηςκαιμεθόδουςχρήσηςτωνενώσεωνσε in vitro εφαρμογές, όπωςη μελέτηκινασώνσεβιολογικάκαιπαθολογικάφαινόμενα, ημελέτηοδώνμεταγωγήςενδοκυτταρικώνσημάτωνπουδιαμεσολαβείταιαπότέτοιεςκινάσεςκαιη συγκριτικήαξιολόγησηνέωναναστολέωνκινασών. Οιενώσειςαυτήςτηςεφεύρεσηςέχουντύπο (I) ήέναφαρμακευτικώςαποδεκτόάλας, όπουοιμεταβλητέςείναιόπωςορίζονταιστοπαρόν. Επιπλέον, οιενώσειςαυτήςτηςεφεύρεσηςέχουντύπο (Ι-Α) ήέναφαρμακευτικώςαποδεκτόάλας, όπουοιμεταβλητέςείναιόπωςορίζονταιστοπαρόν.
-
公开(公告)号:ME03036B
公开(公告)日:2018-10-20
申请号:MEP2018134
申请日:2013-12-06
Applicant: VERTEX PHARMA
Inventor: AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN-MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDLETON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: A61K31/495 , A61P35/00 , C07D487/04
-
-
-
-
-
-
-
-
-